These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 21724551)

  • 21. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
    Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
    Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
    Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
    Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
    Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
    Liu N; Huang H; Xu L; Hua X; Li X; Liu S; Yang C; Zhao C; Zhao C; Li S; Dou QP; Liu J
    Toxicol Lett; 2014 Jan; 224(3):333-40. PubMed ID: 24291039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
    Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
    Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
    Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
    Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
    Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
    Escalante AM; McGrath RT; Karolak MR; Dorr RT; Lynch RM; Landowski TH
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1567-76. PubMed ID: 23572175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
    Tian Z; Zhao JJ; Tai YT; Amin SB; Hu Y; Berger AJ; Richardson P; Chauhan D; Anderson KC
    Blood; 2012 Nov; 120(19):3958-67. PubMed ID: 22983447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.